Dr. David Kim -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. David Kim, a Hepatology physician based in Boston, MA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. David Kim has received $3,601.34 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. David Kim
- Medical Specialty: Hepatology
- Practice Location: Boston, MA, Massachusetts
- NPI Number: 1196690184
- Transparency Score: 75/100
- Payment Records Span: 2025-12-15 to 2025-12-15
Payment Summary
Dr. David Kim has received a total of $3,601.34 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $3,601.34 per transaction.
- Total Payments Received: $3,601.34
- Number of Transactions: 1
- Average Payment: $3,601.34
- Transparency Score: 75/100 -- This score reflects the overall payment profile relative to peers in Hepatology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. David Kim's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Travel & Lodging | $3,601.34 | Transportation and hotel expenses for conferences and meetings |
The largest payment category for Dr. David Kim is Travel & Lodging, accounting for 100% ($3,601.34) of total pharmaceutical payments received. This represents the primary type of financial relationship between Dr. David Kim and pharmaceutical companies.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. David Kim. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Bristol-Myers Squibb | $3,601.34 | 1 |
Dr. David Kim has a financial relationship with Bristol-Myers Squibb, receiving $3,601.34 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. David Kim. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Entresto -- Referenced in payment records from pharmaceutical companies to Dr. David Kim
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. David Kim's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
David Kim has received $3.6K across 1 pharmaceutical payments as a Hepatology physician in Boston, MA. Top paying companies include Bristol-Myers Squibb ($3.6K). Dr. Kim received a single payment of $3,601 in 2025, which is his only recorded payment. This payment was exclusively from Bristol-Myers Squibb, representing 100% of his total reported payments. The payment was categorized as 'travel', indicating the nature of the expense covered by the pharmaceutical company.
Patient Guidance: Questions to Ask Your Doctor
If Dr. David Kim is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Patients should be aware that while pharmaceutical payments are legal, a doctor receiving a large single payment for travel related to a specific drug might have a closer relationship with that drug's manufacturer, which could potentially influence treatment discussions. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. David Kim Compares to Other Hepatology Physicians
For Hepatology specialists, payment profiles vary, but a single large payment from one company for travel related to a specific drug is less common than more diversified or smaller, frequent payments.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. David Kim in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | $3,601.34 | travel | Entresto | 2025-12-15 | Not Assessed |
Frequently Asked Questions About Dr. David Kim's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has David Kim received?
David Kim has received a total of $3.6K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is David Kim taking too much pharma money?
David Kim has received $3.6K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Hepatology), the types of payments, and how they compare to peers. The largest payment category is travel ($3.6K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay David Kim?
The top pharmaceutical companies paying David Kim are: Bristol-Myers Squibb ($3.6K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does David Kim receive?
David Kim's payments by type: travel: $3.6K.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do David Kim's payments compare to other Hepatology doctors?
To compare, look at the total amount ($3.6K), number of payments (1), and the types of payments received. Hepatology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify David Kim's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1196690184). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about David Kim's pharma payment profile?
The entire payment amount is attributed to a single company and a single payment event. David Kim has received $3.6K in total pharma payments.
How does David Kim compare to peers in Hepatology?
For Hepatology specialists, payment profiles vary, but a single large payment from one company for travel related to a specific drug is less common than more diversified or smaller, frequent payments.
Are David Kim's pharma relationships typical for Hepatology?
The payment is linked to a specific drug, 'Entresto', suggesting a potential focus or interaction related to this medication.
What should patients of David Kim know about these payments?
Patients should be aware that while pharmaceutical payments are legal, a doctor receiving a large single payment for travel related to a specific drug might have a closer relationship with that drug's manufacturer, which could potentially influence treatment discussions.
What patterns are visible in David Kim's payment history?
The payment occurred in 2025, indicating recent activity in pharmaceutical payments.
Understanding This Doctor Payment Report
This transparency report for Dr. David Kim is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Hepatology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. David Kim's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. David Kim and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Hepatology Specialty Payment Data -- See payment patterns for all hepatology physicians
- Massachusetts Physician Payments -- Browse pharmaceutical payments to physicians in Massachusetts
- Hepatology Physicians in Massachusetts -- Compare Dr. David Kim to peers in the same state and specialty
- Bristol-Myers Squibb Payment Profile -- View all payments made by Dr. David Kim's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. David Kim's NPI (1196690184) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.